Bionano Genomics officer has 7 shares withheld

Bionano Genomics, Inc. Principal Accounting Officer Mark Adamchak reported a small, routine tax-related share withholding.

Rhea-AI Filing Summary

Bionano Genomics, Inc. Principal Accounting Officer Mark Adamchak reported a small, routine tax-related share withholding. On June 3, 2026, the company withheld 7 shares of common stock at $1.30 per share to cover tax obligations when an RSU award vested. After this non-market disposition, Adamchak directly holds 253 shares of common stock.

Insider Trade Summary

Exercise Price or Tax Liability: 7 shares

Exercise Price or Tax Liability 1 txn

Insider Adamchak Mark

Role Principal Accounting Officer

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	7	$1.30	$9.10

Holdings After Transaction: Common Stock — 253 shares (Direct)

Footnotes (1)

1. F1. The reporting person is reporting the withholding by the Issuer of an aggregate of 7 shares of common stock in connection with shares that vested on June 3, 2026 pursuant to an RSU award granted on June 3, 2024, but that were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the RSU award.

Key Figures

Shares withheld for taxes: 7 shares Withholding price per share: $1.30 per share Shares held after transaction: 253 shares +1 more

4 metrics

Shares withheld for taxes 7 shares Withheld on June 3, 2026 for RSU tax obligations

Withholding price per share $1.30 per share Value used for 7 withheld shares of common stock

Shares held after transaction 253 shares Direct common stock holdings after June 3, 2026 withholding

Tax-withholding share count 7 shares Form 4 taxWithholdingShares in transactionSummary

Key Terms

RSU award, tax withholding obligations, Principal Accounting Officer

3 terms

RSU award financial

"in connection with shares that vested on June 3, 2026 pursuant to an RSU award granted on June 3, 2024"

tax withholding obligations financial

"were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the RSU award"

Principal Accounting Officer financial

"officer_title": "Principal Accounting Officer""

The Principal Accounting Officer is the person responsible for making sure a company's financial records are accurate and follow the rules. They play a key role in preparing financial reports that show how well the company is doing. This helps investors, managers, and regulators trust the company's financial information.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Bionano Genomics (BNGO) report for Mark Adamchak?

Bionano Genomics reported that Principal Accounting Officer Mark Adamchak had 7 shares of common stock withheld on June 3, 2026. The shares were retained by the company to cover tax obligations related to a vesting RSU award, rather than an open-market sale.

Was the Bionano Genomics (BNGO) Form 4 transaction a stock sale?

No, the Form 4 shows a tax-withholding disposition, not an open-market sale. The issuer withheld 7 shares that would otherwise have been issued, to satisfy Mark Adamchak’s tax obligations when his RSU award vested on June 3, 2026.

How many Bionano Genomics (BNGO) shares were involved in the tax withholding?

The filing reports that 7 shares of Bionano Genomics common stock were withheld at a price of $1.30 per share. These shares relate to RSUs that vested on June 3, 2026 and were used solely to cover tax liabilities.

How many Bionano Genomics (BNGO) shares does Mark Adamchak hold after this Form 4?

After the reported tax-withholding disposition, Mark Adamchak directly holds 253 shares of Bionano Genomics common stock. This remaining position is disclosed in the Form 4 as the total number of shares owned following the June 3, 2026 transaction.

What is the origin of the RSU award in the Bionano Genomics (BNGO) Form 4?

The RSU award that triggered the tax withholding was granted on June 3, 2024. Shares under that award vested on June 3, 2026, and 7 shares were withheld by Bionano Genomics to satisfy Principal Accounting Officer Mark Adamchak’s tax obligations at settlement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/03/2026 - 08:50 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Adamchak Mark

(Last) (First) (Middle)

C/O BIONANO GENOMICS, INC.

9540 TOWNE CENTRE DRIVE, SUITE 100

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Bionano Genomics, Inc. [ BNGO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Principal Accounting Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/03/2026		F(1)		7(1)	D	$1.3	253	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reporting person is reporting the withholding by the Issuer of an aggregate of 7 shares of common stock in connection with shares that vested on June 3, 2026 pursuant to an RSU award granted on June 3, 2024, but that were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the RSU award.

	/s/ Jonathan V. Dixon, Attorney-in-Fact	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)